NICE hurries to assess new hepatitis C drugs

The UK's cost-effectiveness watchdog is preparing to assess two new-and-highly-anticipated hepatitis C drugs--Merck's Victrelis and Vertex/Johnson & Johnson's Incivek--even before European regulators clear them for marketing. NICE says the drugs may meet an important medical need, and it wants to quickly move to evaluate them. Report


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.